Protein structure similarity clustering (PSSC) and natural product structure as inspiration sources for drug development and chemical genomics

Current Opinion in Chemical Biology

Volumn 9, Issue 3, 2005, Pages 232-239

  Dekker, Frank J ^a   Koch, Marcus A ^a   Waldmann, Herbert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ACETYLCHOLINESTERASE; BESTATIN; CAPTOPRIL; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSIDIOLIDE; HYDROLASE INHIBITOR; LEUKOTRIENE A4 HYDROLASE; LIGAND; NATURAL PRODUCT; OXIDOREDUCTASE INHIBITOR; PEPTIDASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR;

BIOINFORMATICS; CLUSTER ANALYSIS; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; LIGAND BINDING; MOLECULAR EVOLUTION; MOLECULAR LIBRARY; PHARMACOGENOMICS; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

BIOLOGICAL FACTORS; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, PROTEIN; DRUG DESIGN; GENOMICS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEINS;

EID: 20444409179     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2005.03.003     Document Type: Review

References (52)

1. N.V. Grishin Fold change in evolution of protein structures J Struct Biol 134 2001 167 185
2. A.F.W. Coulson, and J. Moult A unifold, mesofold, and superfold model of protein fold use Proteins 46 2002 61 71 The authors discuss a unifold, mesofold and superfold model for protein folds. Unifolds are found in a single narrow protein family, mesofolds are found in an intermediate number of protein families and superfolds are found in many protein families. The total number of folds is at least 10 000 and 80% of sequence families have one of about 400 folds.
3. E.V. Koonin, Y.I. Wolf, and G.P. Karev The structure of the protein universe and genome evolution Nature 420 2002 218 223 The authors argue that no more than 10 000 folds exist. Moreover, the distribution of proteins among these folds is highly non-homogeneous. Some folds and superfamilies are extremely abundant, but most are rare. It seems certain that the great majority of protein families belong to about 1000 common folds.
4. H. Leonov, J.S.B. Mitchell, and I.T. Arkin Monte Carlo estimation of the number of possible protein folds: effects of sampling bias and folds distributions Proteins 51 2003 352 359
5. A. Grant, D. Lee, and C. Orengo Progress towards mapping the universe of protein folds Genome Biol 5 2004 107 Excellent discussion of how well the current set of known proteins and protein folds can be used to estimate the total number of folds in nature.
6. M.A. Koch, R. Breinbauer, and H. Waldmann Protein structure similarity as guiding principle for combinatorial library design Biol Chem 384 2003 1265 1272
7. M.A. Koch, L. Wittenberg, S. Basu, D.A. Jeyaraj, E. Gourzoulidou, K. Reinecke, A. Odermatt, and H. Waldmann Compound library development guided by protein structure similarity clustering and natural product structure Proc Natl Acad Sci USA 101 2004 16721 16726 The paper describes protein structure similarity clustering in conjunction with natural product structure as inspiration source for compound library design.
8. M.A. Koch, and H. Waldmann Natural product-derived compound libraries and protein structure similarity as guiding principles for the discovery of drug candidates H. Kubinyi G. Müller Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective 2004 Wiley-VCH 377 403
9. S. Rose Statistical design and application to combinatorial chemistry Drug Discov Today 7 2002 133 138
10. N.P. Savchuk, K.V. Balakin, and S.E. Tkachenko Exploring the chemogenomic knowledge space with annotated chemical libraries Curr Opin Chem Biol 8 2004 412 417 A comprehensive review on annotated chemical libraries as an information basis for design of target-directed combinatorial libraries.
11. D.E. Root, S.P. Flaherty, B.P. Kelly, and B.R. Stockwell Biological mechanism profiling using an annotated compound library Chem Biol 10 2003 881 892
12. S.L. Schreiber Target-oriented and diversity-oriented organic synthesis in drug discovery Science 287 2000 1964 1969
13. M.D. Burke, and S.L. Schreiber A planning strategy for diversity-oriented synthesis Angew Chem Int Ed Engl 43 2004 46 58 A comprehensive review on forward synthetic planning to generate diverse combinatorial libraries.
14. J. Sadowski, and H. Kubinyi A scoring scheme for discriminating between drugs and nondrugs J Med Chem 41 1998 3325 3329
15. Ajay, W.P. Walters, and M.A. Murcko Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? J Med Chem 41 1998 3314 3324
16. W.P. Walters, Ajay, and M.A. Murcko Recognizing molecules with drug-like properties Curr Opin Chem Biol 3 1999 384 387
17. R. Breinbauer, I.R. Vetter, and H. Waldmann From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries Angew Chem Int Ed Engl 41 2002 2879 2890 The authors argue that conservatism in protein folds can be exploited as an inspiration source for compound library design. Natural products can be considered as biologically validated starting points in structural space to design compound libraries.
18. D. Brohm, S. Metzger, A. Bhargava, O. Müller, F. Lieb, and H. Waldmann Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of Dysidiolide-derived phosphatase inhibitors Angew Chem Int Ed Engl 41 2002 307 311
19. D.J. Newman, G.M. Cragg, and K.M. Snader Natural products as sources of new drugs over the period 1981-2002 J Nat Prod 66 2003 1022 1037 The authors analyzed new drugs over the period 1981-2002 and found that the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Furthermore, they were not able to identify a de novo combinatorial compound approved as a drug in this time frame.
20. A. Ganesan Natural products as a hunting ground for combinatorial chemistry Curr Opin Biotechnol 15 2004 584 590
21. A. Boldi Libraries from natural product-like scaffolds Curr Opin Chem Biol 8 2004 281 286
22. B.E. Evans, K.E. Rittle, M.G. Bock, R.M. DiPardo, R.M. Freidinger, W.L. Whitter, G.F. Lundell, D.F. Veber, P.S. Anderson, and RS.L. Chang Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists J Med Chem 31 1988 2235 2246
23. G. Müller Medicinal chemistry of target family-directed masterkeys Drug Discov Today 8 2003 681 691 This review describes privileged structures that address various target families of interest.
24. S.V. Frye Structure-activity relationship homology (SARAH) a conceptual framework for drug discovery in the genomic era Chem Biol 6 1999 R3 R7
25. D.C. Greenbaum, W.D. Arnold, F. Lu, L. Hayrapetian, A. Baruch, J. Krumrine, S. Toba, K. Chehade, D. Brömme, and I.D. Kuntz Small molecule affinity fingerprinting: a tool for enzyme family subclassification, target identification, and inhibitor design Chem Biol 9 2002 1085 1094 The authors demonstrate that related enzymes can be clustered on the basis of structure-activity relationships. Such clustering could ultimately aid design of inhibitors that show the proper selectivity.
26. C.P. Ponting, J. Schultz, R.R. Copley, M.A. Andrade, and P. Bork Evolution of domain families Adv Protein Chem 54 2000 185 244
27. G. Apic, J. Gough, and S.A. Teichmann An insight into domain combinations Bioinformatics 17 2001 S83 S89
28. C. Chothia, J. Gough, C. Vogel, and S.A. Teichmann Evolution of the protein repertoire Science 300 2003 1701 1703 The authors describe how multiple domain proteins evolved by gene duplication, recombination and divergence.
29. J. Liu, and B. Rost Domains, motifs and clusters in the protein universe Curr Opin Chem Biol 7 2003 5 11
30. R.B. Russell, P.D. Sasieni, and M.J.E. Sternberg Supersites within superfolds. Binding site similarity in the absence of homology J Mol Biol 282 1998 903 918
31. A. Stark, A. Shkumatov, and R.B. Russell Finding functional sites in structural genomics proteins Structure 12 2004 1405 1412 The authors demonstrate how searches for similar functional sites complement those for similar folds. A strategy combining both methods will facilitate assigning functions to structurally resolved proteins.
32. 4 hydrolase as a target for cancer prevention and therapy Curr Cancer Drug Targets 4 2004 267 283
33. 4 hydrolase: Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes J Biol Chem 266 1991 1375 1378
34. 4 hydrolase J Med Chem 36 1993 211 220
35. 4 hydrolase Bioorg Med Chem 3 1995 1405 1415
36. L. Holm, and C. Sander Mapping the protein universe Science 273 1996 595 602
37. I.N. Shindyalov, and P.E. Bourne Protein structure alignment by incremental combinatorial extension (CE) of the optimal path Protein Eng 11 1998 739 747
38. I.N. Shindyalov, and P.E. Bourne A database and tools for 3-D protein structure comparison and alignment using the combinatorial extension (CE) algorithm Nucleic Acids Res 29 2001 228 229
39. M.A. Lyon, A.P. Ducruet, P. Wipf, and J.S. Lazo Dual-specificity phosphatases as targets for antineoplastic agents Nat Rev Drug Discov 1 2002 961 976
40. E.B. Fauman, J.P. Cogswell, B. Lovejoy, W.J. Rocque, W. Holmes, V.G. Montana, H. Piwnica-Worms, M.J. Rink, and M.A. Saper Crystal structure of the catalytic domain of the human cell cycle control phosphatase Cdc25A Cell 93 1998 617 625
41. Bialy L, Waldmann H: Protein tyrosine phosphatase inhibitors: Next generation drugs? Angew Chem Int Ed Engl 2005, in press.
42. M. Racchi, M. Mazzucchelli, E. Porrello, C. Lanni, and S. Govoni Acetylcholinesterase inhibitors: novel activities of old molecules Pharmacol Res 50 2004 441 451
43. B.R. Walker, and J.R. Seckl 11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease Expert Opin Ther Targets 7 2003 771 783
44. G.P. Chrousos Is 11β-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc Natl Acad Sci USA 101 2004 6329 6330
45. H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J.S. Flier A transgenic model of visceral obesity and the metabolic syndrome Science 294 2001 2166 2170
46. R.A.S. Schweizer, A.G. Atanasov, B.M. Frey, and A. Odermatt A rapid screening assay for inhibitors of 11β-hydroxysteroid dehydrogenases (11β-HSD): flavanone selectively inhibits 11β-HSD1 reductase activity Mol Cell Endocrinol 212 2003 41 49
47. S.A. Ross, E.A. Gulve, and M. Wang Chemistry and biochemistry of type 2 diabetes Chem Rev 104 2004 1255 1282
48. T.C. Sandeep, J.L.W. Yau, A.M.J. MacLullich, J. Noble, I.J. Deary, B.R. Walker, and J.R. Seckl 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics Proc Natl Acad Sci USA 101 2004 6734 6739
49. M.I. New, and R.C. Wilson Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralcorticoid excess Proc Natl Acad Sci USA 96 1999 12790 12797
50. S.P. Gunasekera, P.J. McCarthy, and M. Kelly-Borges Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean Sponge Dysidea etheria de Laubenfels J Am Chem Soc 118 1996 8759 8760
51. D. Brohm, N. Philippe, S. Metzger, A. Bhargava, O. Müller, F. Lieb, and H. Waldmann Solid-phase synthesis of Dysidiolide-derived protein phosphatase inhibitors J Am Chem Soc 124 2002 13171 13178
52. Koch MA, Waldmann H: Protein structure similarity clustering (PSSC) and natural product structure as guiding principles in drug discovery. Drug Discov Today 2005, 10:in press.